Emodin, a Naturally Occurring Anthraquinone Derivative, Ameliorates Dyslipidemia by Activating AMP-Activated Protein Kinase in High-Fat-Diet-Fed Rats

Table 1

Changes on the body weight (BW), food, and water intake in HFD-fed rats receiving 8-week treatment with emodin or pioglitazone.

Groups	Initial BW (g rat^−1)	BW gain (g rat^−1)	Food intake (g rat^−1 per day)	Water intake (mL rat^−1 per day)
RCD-fed
Vehicle	172.5±7.7	17.8 ± 6.2^b	19.3±5.9	77.2±8.1
HFD-fed
Vehicle	173.4±6.9	53.7±7.0	20.3±6.7	86.3±9.4
Emodin (mg kg^−1 per day)
40	173.1±8.4	30.7 ± 6.9^a	21.8±6.9	80.8±9.7
80	172.8±6.7	23.6 ± 5.3^b	20.3±6.3	78.1±7.9
Pioglitazone (20 mg kg^−1 per day)	171.6±8.1	20.4 ± 5.8^b	19.9±7.1	76.7±8.9

Emodin or pioglitazone was dissolved in distilled water for oral administration at the desired doses in a volume of 2 mL kg⁻¹ once a day into HFD-fed rats. The vehicle (distilled water) used to dissolve the tested medications was given at the same volume. Values (mean ± SEM) were obtained from each group of 8 animals in each group after 8 weeks of the experimental period. ^a𝑃<.05 and ^b𝑃<.01 compared to the values of vehicle-treated HFD-fed rats in each group, respectively.